Table 2.
Factors Associated with Plasma HIV Viral Load <400 Copies/ml at Week 48 Among 108 Patients in Unadjusted and Multivariate Logistic Regression Analyses
| VL <400 c/ml (n = 61) | VL >400 c/ml (n = 34) | Unadjusted OR (95% CI) | Adjusted OR (95% CI) | |
|---|---|---|---|---|
| Propensity score (age, gender, race, insurance; OR for 10% increment) | ||||
| Mean ± SD | 0.47 ± 0.14 | 0.46 ± 0.14 | 1.07 (0.80–1.44) | 0.82 (0.55–1.23) |
| HIV VL, log10 copies/ml 0 | ||||
| Mean ± SD | 4.05 ± 1.17 | 4.50 ± 1.00 | 0.68 (0.45–1.04) | 0.63 (0.37–1.07) |
| CD4+, cells/mm3 (O.R. per 50 cells) | ||||
| Mean ± SD | 246 ± 193 | 163 ± 191 | 1.14 (1.00–1.30) | 1.14 (0.99–1.32) |
| Active drugs | ||||
| 1 or 2 | 22 (36.1%) | 15 (44.1%) | 1.0 | 1.0 |
| 3 or 4 | 28 (45.9%) | 12 (35.3%) | 1.59 (0.62–4.08) | 0.91 (0.31–2.73) |
| Unknown | 11 (18.0%) | 7 (20.6%) | 1.07 (0.34–3.39) | 0.63 (0.15–2.76) |
| Strategy | ||||
| PI-sparing | 10 (16.4%) | 12 (35.4%) | 1.0 | 1.0 |
| Other-PI1 | 19 (31.1%) | 11 (32.3%) | 2.07 (0.68–6.36) | 2.85 (0.73–11.21) |
| Darunavir/r | 32 (52.5%) | 11 (32.3%) | 3.49 (1.18–10.31) | 5.77 (1.62–20.58) |
| Raltegravir | ||||
| No | 19 (31.2%) | 18 (52.9%) | 1.0 | 1.0 |
| Yes | 42 (68.8%) | 16 (47.1%) | 2.49 (1.05–5.90) | 3.84 (1.23–11.95) |
1
Included atazanavir (n = 17; 12 ritonavir boosted, 5 no ritonavir), lopinavir/ritonavir (n = 11), fosamprenavir/ritonavir (n = 2), nelfinavir (n = 1), and one regimen with both atazanavir and lopinavir/ritonavir.